 |
Amarin to Present at the UBS Global Life Sciences Conference
19 Sep 2011
|
58.3 KB |
|
| |
BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 19, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Joseph Zakrzewski, Amarin's Executive Chairman and Chief Executive Officer, is scheduled to present at the UBS Global Life Sciences Con...
|
|
Amarin Announces Successful MARINE Phase 3 Clinical Trial Results Published in The American Journal of Cardiology
1 Sep 2011
|
63.0 KB |
|
| |
BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 1, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that results of its pivotal MARINE Phase 3 clinical trial were published in the September issue of The American Journal of Cardiology. The C...
|
|
Data From Amarin's AMR101 Phase 3 MARINE Trial to be Presented at the European Society of Cardiology (ESC) Congress 2011
25 Aug 2011
|
61.7 KB |
|
| |
BEDMINSTER, N.J., and DUBLIN, Ireland, Aug. 25, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that data from the pivotal Phase 3 MARINE trial investigating AMR101 as a treatment for very high triglycerides (≥500 mg/dL)will be pr...
|
|
Amarin to Present at the Wedbush Securities Life Sciences Management Access Conference
12 Aug 2011
|
10.9 KB |
|
| |
MYSTIC, Conn. and DUBLIN, Ireland, Aug. 12, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Joseph Zakrzewski, Amarin's Executive Chairman and Chief Executive Officer, will present at the Wedbush Securities 2011 Life Sciences Manag...
|
|
Amarin Announces Agreement From FDA on Special Protocol Assessment for AMR101 Outcomes Study
10 Aug 2011
|
15.7 KB |
|
| |
MYSTIC, Conn. and DUBLIN, Ireland, Aug. 10, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) agreement for the design o...
|
|
Amarin Reports Second Quarter 2011 Results
9 Aug 2011
|
71.2 KB |
|
| |
- Company on Track for NDA Filing This Quarter -
- Conference Call Set for 8:00 am EDT August 10 -
MYSTIC, Conn. and DUBLIN, Aug. 9, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company focused on cardiovascular disease, today reported financial and operating results for the quar...
|
|
Amarin to Present at the 2011 Canaccord Genuity Growth Conference
8 Aug 2011
|
11.0 KB |
|
| |
MYSTIC, Conn. and DUBLIN, Aug. 8, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that John Thero, Amarin's President, will present at the 2011 Canaccord Genuity Growth Conference to be held at the Intercontinental Hotel in Boston. The ...
|
|
Amarin Announces Q2, 2011 Results Conference Call
8 Aug 2011
|
11.2 KB |
|
| |
MYSTIC, Conn. and DUBLIN, Aug. 8, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company focused on cardiovascular disease, has scheduled a conference call with members of senior management to discuss the Company's financial results and business initiatives for its fiscal second quarter on Wednesda...
|
|
Phase 3 ANCHOR and MARINE Trial Data to be Presented in November at the American Heart Association's Scientific Sessions
4 Aug 2011
|
57.4 KB |
|
| |
MYSTIC, Conn. and DUBLIN, Ireland, Aug. 4, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that data from each of its two pivotal Phase 3 studies, the ANCHOR trial and the MARINE trial, will be presented at the American Heart Associatio...
|
|
Amarin Successfully Completes All Remaining Clinical Studies for AMR101 NDA
1 Aug 2011
|
60.5 KB |
|
| |
MYSTIC, Conn. and DUBLIN, Ireland, Aug. 1, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, announced today the successful completion of all remaining studies required for the Company's planned new drug application (NDA) for AMR101 for the treatment of ...
|
|
Amarin Completes All Non-Clinical Work for AMR101 NDA Submission
7 Jul 2011
|
60.9 KB |
|
| |
MYSTIC, Conn. and DUBLIN, July 7, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, announced today the successful completion of the remaining non-clinical studies for the Company's planned new drug application (NDA) for AMR101 for the treatment of patie...
|
|
Amarin to Present at the Jefferies 2011 Global Healthcare Conference
1 Jun 2011
|
10.9 KB |
|
| |
MYSTIC, Conn. and DUBLIN, Ireland, June 1, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Joseph Zakrzewski, Amarin's Executive Chairman and Chief Executive Officer, will present at the Jefferies 2011 Global Healthcare Conference ...
|
|
Amarin Announces Global Supply Network for AMR101
31 May 2011
|
16.8 KB |
|
| |
MYSTIC, Conn. and DUBLIN, May 31, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, announced today the expansion of its capability to supply AMR101 through the addition of two active pharmaceutical ingredient (API) suppliers and two encapsulators.
...
|
|
Additional Detail of Successful MARINE Phase III Trial to be Presented at the National Lipid Association 2011 Annual Scientific Sessions
19 May 2011
|
17.7 KB |
|
| |
NEW YORK, May 19, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today summarized additional MARINE Phase 3 pivotal trial results being presented at the National Lipid Association 2011 Annual Scientific Sessions (NLA) in New York City. In November 201...
|
|
Amarin-Sponsored Posters to be Presented Today at the National Lipid Association 2011 Annual Scientific Sessions
19 May 2011
|
52.7 KB |
|
| |
-EPA Therapy Demonstrates a Wide Range of Lipid Lowering Benefits
Without the LDL-C Increase as Seen With Omega-3s Containing DHA-
-Amarin's AMR101 Contains >96% EPA-
NEW YORK, May 19, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular diseas...
|
|
Amarin Reports First Quarter 2011 Results
10 May 2011
|
23.3 KB |
|
| |
DUBLIN and MYSTIC, Conn., May 10, 2011 /PRNewswire/ -- Amarin Corporation plc (NASDAQ: AMRN), a clinical-stage biopharmaceutical company focused on cardiovascular disease, today reported financial results for the quarter ended March 31, 2011 (Q1 2011). The Company also provided an update on its business progress related to the development program o...
|
|
Amarin to Present at the Deutsche Bank 26th Annual Healthcare Conference
26 Apr 2011
|
10.3 KB |
|
| |
MYSTIC, Conn. and DUBLIN, April 26, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that John Thero, Amarin's President, will present at the Deutsche Bank 26th Annual Healthcare Conference to be held at the InterContinental Hotel in Boston...
|
|
Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C
18 Apr 2011
|
68.9 KB |
|
| |
MYSTIC, Conn. and DUBLIN, April 18, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from its ANCHOR trial for the Company's lead product candidate, AMR101. The Phase 3 trial met its prima...
|
|
Phase 3 MARINE Trial Data to be Presented in May at the National Lipid Association 2011 Annual Scientific Sessions
5 Apr 2011
|
62.7 KB |
|
| |
MYSTIC, Conn. and DUBLIN, April 5, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that data from the MARINE trial, a pivotal Phase 3 study investigating AMR101 as a treatment for very high triglycerides (≥500 mg/dL), will be present...
|
|
Amarin to Present at the 10th Annual Needham Healthcare Conference
31 Mar 2011
|
10.3 KB |
|
| |
MYSTIC, Conn. and DUBLIN, March 31, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Executive Chairman and Chief Executive Officer, Joseph Zakrzewski, will present at 8:40 a.m. EDT on April, 6, 2011 at the 10th Annual Needham Healthca...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter